IXICO Toekomstige groei

Future criteriumcontroles 0/6

De verwachting is dat IXICO de winst en omzet met respectievelijk 5.5% en 1.8% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 38.7% per jaar.

Belangrijke informatie

5.5%

Groei van de winst

38.7%

Groei van de winst per aandeel

Life Sciences winstgroei	19.8%
Inkomstengroei	1.8%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	08 Oct 2024

Recente toekomstige groei-updates

Recent updates

IXICO plc (LON:IXI) May Have Run Too Fast Too Soon With Recent 28% Price Plummet

Mar 24

At UK£1.04, Is It Time To Put IXICO plc (LON:IXI) On Your Watch List?

Mar 22

Does IXICO's (LON:IXI) Statutory Profit Adequately Reflect Its Underlying Profit?

Feb 22

Did Business Growth Power IXICO's (LON:IXI) Share Price Gain of 146%?

Feb 01

Will Weakness in IXICO plc's (LON:IXI) Stock Prove Temporary Given Strong Fundamentals?

Jan 09

I Ran A Stock Scan For Earnings Growth And IXICO (LON:IXI) Passed With Ease

Dec 22

Who Has Been Selling IXICO plc (LON:IXI) Shares?

Dec 04

What Does IXICO plc's (LON:IXI) Share Price Indicate?

Jul 06

Winst- en omzetgroeiprognoses

AIM:IXI - Toekomstschattingen van analisten en financiële gegevens uit het verleden (GBP Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
9/30/2025	6	-2	-2	-2	1
9/30/2024	6	-2	-2	-2	1
3/31/2024	6	-2	-2	-1	N/A
12/31/2023	6	-2	-2	0	N/A
9/30/2023	7	-1	-2	0	N/A
6/30/2023	7	-1	-1	1	N/A
3/31/2023	8	0	-1	1	N/A
12/31/2022	8	1	-1	1	N/A
9/30/2022	9	1	-1	1	N/A
6/30/2022	8	1	-1	1	N/A
3/31/2022	8	1	-1	1	N/A
12/31/2021	9	1	-1	1	N/A
9/30/2021	9	2	-2	1	N/A
6/30/2021	10	1	-1	1	N/A
3/31/2021	10	1	0	2	N/A
12/31/2020	10	1	0	2	N/A
9/30/2020	10	1	1	2	N/A
6/30/2020	9	1	0	1	N/A
3/31/2020	9	1	-1	0	N/A
12/31/2019	8	1	-1	0	N/A
9/30/2019	8	0	-1	0	N/A
6/30/2019	7	0	-1	0	N/A
3/31/2019	6	0	0	0	N/A
12/31/2018	6	0	0	0	N/A
9/30/2018	5	-1	0	0	N/A
6/30/2018	5	-1	N/A	N/A	N/A
3/31/2018	5	-1	0	0	N/A
12/31/2017	4	-1	N/A	0	N/A
9/30/2017	4	-2	N/A	-1	N/A
6/30/2017	4	-2	N/A	N/A	N/A
3/31/2017	4	-2	N/A	0	N/A
12/31/2016	4	-2	N/A	-1	N/A
9/30/2016	3	-2	N/A	-2	N/A
6/30/2016	3	-2	N/A	N/A	N/A
3/31/2016	3	-2	N/A	-2	N/A
12/31/2015	3	-1	N/A	-1	N/A
9/30/2015	3	-1	N/A	-1	N/A
3/31/2015	3	-1	N/A	-1	N/A
12/31/2014	3	-1	N/A	-2	N/A
9/30/2014	3	-2	N/A	-2	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat IXI de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat IXI de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat IXI de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van IXI ( 1.8% per jaar) zal naar verwachting langzamer groeien dan de markt UK ( 3.6% per jaar).

Hoge groei-inkomsten: De omzet van IXI ( 1.8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van IXI naar verwachting over 3 jaar hoog zal zijn

IXICO Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus estimates of losses per share improve by 16%

Ixico plc Provides Revenue Guidance for the Year Ending 30 September 2024

IXICO plc Provides Earnings Guidance for the Full Year of 2023

IXICO plc Provides Earnings Guidance for Six Months to 31 March 2023 and Full Year of 2024

IXICO plc Provides Revenue Guidance for the Year Ending September 30, 2024

IXICO plc Provides Revenue Guidance for the Financial Year 2023

Recent updates

IXICO plc to Report Fiscal Year 2024 Results on Dec 04, 2024

New major risk - Shareholder dilution

Consensus estimates of losses per share improve by 16%

Ixico plc Provides Revenue Guidance for the Year Ending 30 September 2024

IXICO plc Appoints Bram Goorden as Chief Executive Officer, Effective 19 August 2024

New major risk - Revenue and earnings growth

IXICO plc to Report First Half, 2024 Results on May 21, 2024

New minor risk - Share price stability

Giulio Cerroni to Retire as CEO of IXICO plc, Effective End of 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

IXICO plc, Annual General Meeting, Jan 25, 2024

IXICO plc to Report Fiscal Year 2023 Results on Dec 05, 2023

New major risk - Market cap size

Ixico plc Appoints Dipti Amin as an Independent Non-Executive Director and the Remuneration and Audit Committees

New major risk - Revenue and earnings growth

IXICO plc Provides Earnings Guidance for the Full Year of 2023

First half 2023 earnings released: UK£0.015 loss per share (vs UK£0.004 profit in 1H 2022)

IXICO plc to Report First Half, 2023 Results on May 23, 2023

IXICO plc Provides Earnings Guidance for Six Months to 31 March 2023 and Full Year of 2024

IXICO plc Provides Revenue Guidance for the Year Ending September 30, 2024

Full year 2022 earnings: EPS and revenues exceed analyst expectations

IXICO plc, Annual General Meeting, Jan 27, 2023

Less than half of directors are independent

Is IXICO plc (LON:IXI) Potentially Undervalued?

IXICO plc Provides Revenue Guidance for the Financial Year 2023

First half 2022 earnings released

Less than half of directors are independent

IXICO plc Provides Revenue Guidance for the Six Months Ended March 31, 2022

Is It Time To Consider Buying IXICO plc (LON:IXI)?

If You Like EPS Growth Then Check Out IXICO (LON:IXI) Before It's Too Late

IXICO plc Announces the Launch of IXIQ.Ai, A Novel Platform for Brain Segmentation Based on Convolutional Neural Networks

IXICO plc Appoints Lynne Hughes as Senior Therapeutic Advisor

IXICO plc Appoints Lynne Hughes as Senior Therapeutic Advisor

Full year 2021 earnings: EPS exceeds analyst expectations

Here's Why I Think IXICO (LON:IXI) Is An Interesting Stock

Should You Think About Buying IXICO plc (LON:IXI) Now?

Here's Why I Think IXICO (LON:IXI) Is An Interesting Stock

First half 2021 earnings released: EPS UK£0.018 (vs UK£0.01 in 1H 2020)

Investor sentiment improved over the past week

IXICO plc Provides Earnings Guidance for the Six Months Ended 31 March 2021

Here's Why I Think IXICO (LON:IXI) Is An Interesting Stock

IXICO plc announced that it has received £1.2 million in funding from Merchant Capital Manager Limited

IXICO plc (LON:IXI) May Have Run Too Fast Too Soon With Recent 28% Price Plummet

At UK£1.04, Is It Time To Put IXICO plc (LON:IXI) On Your Watch List?

New 90-day high: UK£1.08

Investor sentiment improved over the past week

IXICO plc Announces Collaboration with Microsoft

Ixico plc Announces That It Has Been Selected by A Current Mid-Sized Biopharmaceutical Client to Support the Company's Phase Ii Alzheimer's Disease Clinical Trial

IXICO plc Announces That It Has Been Selects by Cyclerion Therapeutics, Inc

CEO & Director exercised options and sold UK£140k worth of stock

Does IXICO's (LON:IXI) Statutory Profit Adequately Reflect Its Underlying Profit?

Did Business Growth Power IXICO's (LON:IXI) Share Price Gain of 146%?

New 90-day low: UK£0.86

Will Weakness in IXICO plc's (LON:IXI) Stock Prove Temporary Given Strong Fundamentals?

IXICO Secures New Contract for £3.4 Million

I Ran A Stock Scan For Earnings Growth And IXICO (LON:IXI) Passed With Ease

Who Has Been Selling IXICO plc (LON:IXI) Shares?

Revenue and earnings beat expectations

Full year 2020 earnings released: EPS UK£0.02

IXICO plc, Annual General Meeting, Jan 21, 2021

IXICO plc Announces £1.9 Million New Study Award

New 90-day high: UK£1.14

IXICO plc to Report Fiscal Year 2020 Results on Dec 02, 2020

Market bids up stock over the past week

New 90-day high: UK£1.07

IXICO plc and NYU Langone Health Signs Agreement

IXICO plc Announces £2 Million Contract Extension Win - Huntington’s Disease

New 90-day high: UK£0.97

Ixico plc Enters into 5 Year Collaboration with Friedreich's Ataxia Research Alliance